{"disease":{"id":"metastatic-gastrointestinal-stromal-tumor","name":"metastatic gastrointestinal stromal tumor"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02500797","title":"Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":164,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06772233","title":"A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT01738139","title":"Ipilimumab and Imatinib Mesylate in Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT01735955","title":"Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02216578","title":"Ph II CABOGIST in GIST","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT04595747","title":"Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}